Chemkart India Ltd — Important, 12-11-2025: Company Update

Chemkart India Ltd. released its H1 FY26 investor presentation. For the first half, consolidated revenue stood at 103.23 Cr, down 8.75% year-on-year. EBITDA was 14.16 Cr, a 30.02% decrease, and PAT reached 10.15 Cr, declining 35.07%. Management noted industry-wide price corrections and reduced Glycine exports impacted results, despite higher sales volumes for products like Creatine Monohydrate. Prices are now stabilizing, and the company anticipates stronger H2 growth. A significant strategic highlight is the ongoing construction of a greenfield nutraceutical manufacturing facility in the JNPT SEZ for exports.